{
    "Trade/Device Name(s)": [
        "CardioMPO Test",
        "CardioMPO Reagent Kit",
        "CardioMPO Calibrator Kit",
        "CardioMPO Control Kit"
    ],
    "Submitter Information": "PrognostiX, Inc.",
    "510(k) Number": "K050029",
    "Predicate Device Reference 510(k) Number(s)": [
        "K030477"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NTV",
        "JJX",
        "JIS"
    ],
    "Summary Letter Date": "May 10, 2005",
    "Summary Letter Received Date": "April 20, 2005",
    "Submission Date": "April 19, 2005",
    "Regulation Number(s)": [
        "21CFR866.5600"
    ],
    "Regulation Name(s)": [
        "Low-density lipoprotein immunological test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Myeloperoxidase"
    ],
    "Specimen Type(s)": [
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)",
        "ELISA"
    ],
    "Methodologies": [
        "Sandwich immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for CardioMPO Test, a sandwich enzyme immunoassay for quantitative determination of myeloperoxidase in human plasma to assess risk of major adverse cardiac events.",
    "Indications for Use Summary": "Quantitative determination of myeloperoxidase in human plasma, used with clinical history, ECG and cardiac biomarkers to evaluate patients with chest pain at risk for major adverse cardiac events including myocardial infarction, need for revascularization, or death.",
    "fda_folder": "Immunology"
}